Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT02378480 is registered in ClinicalTrials.gov with Paratek Pharmaceuticals Inc as lead sponsor.

NCT NCT02378480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02378480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Lead sponsor
Paratek Pharmaceuticals Inc
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2015
Completion date
May 31, 2016
Enrollment
655 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial infections, skin structures and soft tissue infections